Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

Cardiomyopathies are diseases of the heart muscle. This group of pathological conditions includes dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic ...

Ibrahima Diack and Magatte N'Diaye are given "adopted sons of the city" status in A Coruña. Graham Caldew is cycling the length of Spain to raise money for a charity which helped his daughter. A ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

A man has been arrested on suspicion of attempted murder after a van struck two people in Poulton Le-Fylde just after midnight. Police received a report at 12.50am today, Sunday, that a Ford ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth. Click here to read why ALNY is a Buy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

Among patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), vutrisiran reduced the risk of outpatient worsening heart failure (HF) – which was itself associated with a 2.6-fold increased ...